Tetraphase Pharmaceuticals Inc (TTPH) Given Consensus Rating of “Hold” by Brokerages

Shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) have been assigned a consensus rating of “Hold” from the eight ratings firms that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $17.00.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 12th. HC Wainwright upped their price objective on shares of Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, November 6th. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, BidaskClub cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at $5.15 on Monday. The stock has a market cap of $265.71, a PE ratio of -1.80 and a beta of 2.29. Tetraphase Pharmaceuticals has a 52-week low of $4.14 and a 52-week high of $9.93.

In other news, Director L Patrick Gage acquired 3,880 shares of the business’s stock in a transaction that occurred on Wednesday, November 29th. The stock was acquired at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the transaction, the director now directly owns 38,880 shares of the company’s stock, valued at approximately $250,776. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jacques Dumas sold 8,750 shares of the company’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total transaction of $54,425.00. Following the sale, the insider now directly owns 8,750 shares of the company’s stock, valued at approximately $54,425. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. raised its stake in Tetraphase Pharmaceuticals by 0.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock worth $925,000 after acquiring an additional 874 shares in the last quarter. Voya Investment Management LLC raised its stake in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 3,104 shares in the last quarter. Alliancebernstein L.P. raised its stake in Tetraphase Pharmaceuticals by 6.9% during the second quarter. Alliancebernstein L.P. now owns 59,200 shares of the biopharmaceutical company’s stock worth $422,000 after acquiring an additional 3,800 shares in the last quarter. California Public Employees Retirement System raised its stake in Tetraphase Pharmaceuticals by 2.0% during the second quarter. California Public Employees Retirement System now owns 242,200 shares of the biopharmaceutical company’s stock worth $1,727,000 after acquiring an additional 4,800 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Tetraphase Pharmaceuticals by 3.3% during the second quarter. Bank of New York Mellon Corp now owns 194,144 shares of the biopharmaceutical company’s stock worth $1,384,000 after acquiring an additional 6,247 shares in the last quarter. 58.36% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/02/12/tetraphase-pharmaceuticals-inc-ttph-given-consensus-rating-of-hold-by-brokerages.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply